Nurix Therapeutics, Inc.

For the period ended Nov 30, 2025. Filed Jan 28, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Jan 28, 2026

NRIX$16.14+5.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Cash Flows

(in thousands)

	Year Ended November 30,
	2025	2024	2023
Cash flows from operating activities
Net loss	$(264,457)	$(193,569)	$(143,948)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	8,740	9,318	7,533
Stock-based compensation	37,965	33,929	33,673
Net accretion of discount on marketable securities	(10,322)	(11,288)	(5,421)
Loss on disposal of property and equipment	89	31	556
Amortization of operating lease right-of-use assets	10,116	7,110	6,121
Other	—	286	—
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(6,229)	(459)	2,139
Accounts payable	(630)	5,209	1,614
Deferred revenue	(36,980)	(28,549)	19,513
Operating lease liabilities	(5,067)	(6,418)	(6,268)
Accrued expenses and other current liabilities	17,310	11,816	3,123
Net cash used in operating activities	(249,465)	(172,584)	(81,365)
Cash flows from investing activities
Purchases of marketable securities	(455,688)	(707,953)	(246,334)
Maturities of marketable securities	617,543	459,513	323,036
Purchases of property and equipment	(14,002)	(9,273)	(8,401)
Net cash provided by (used in) investing activities	147,853	(257,713)	68,301
Cash flows from financing activities
Proceeds from issuances of common stock and pre-funded warrants, net of issuance costs	234,762	188,732	—
Proceeds from exercise of stock options and pre-funded warrants	1,651	5,055	988
Proceeds from issuance of common stock under employee stock purchase plan	2,229	2,132	2,229
Proceeds from issuances of common stock in "at the market" financing, net of issuance costs	—	289,763	—
Repurchase of unvested early exercised stock options	—	(15)	—
Net cash provided by financing activities	238,642	485,667	3,217
Net increase (decrease) in cash, cash equivalents and restricted cash	137,030	55,370	(9,847)
Cash, cash equivalents and restricted cash at beginning of period	110,898	55,528	65,375
Cash, cash equivalents and restricted cash at end of period	$247,928	$110,898	$55,528
Supplemental disclosures of non-cash investing and financing activities:
Additions to property and equipment included in accounts payable and accrued expenses and other current liabilities	$1,183	$1,643	$632
Right-of-use assets recognized in exchange for lease obligations	$32,494	$4,107	$23,995
Capitalized stock-based compensation related to internal-use software development	$20	$14	$74
Issuance costs related to equity financing included in accrued expenses and other current liabilities	$371	$—	$—
Deferred issuance costs included in accounts payable and accrued expenses and other current liabilities	$—	$117	$—
Deferred issuance costs recognized related to the "at the market" financing	$—	$394	$—
Vesting of early exercised stock options	$—	$33	$117

	As of November 30,
	2025	2024	2023
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$246,960	$109,997	$54,627
Restricted cash	968	901	901
Total cash, cash equivalents and restricted cash	$247,928	$110,898	$55,528

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.